Welcome to our dedicated page for Inmode Ltd. news (Ticker: INMD), a resource for investors and traders seeking the latest updates and insights on Inmode Ltd. stock.
News about InMode Ltd. (INMD) centers on its role as a global provider of medical technologies based on novel radio frequency (RF) energy, along with its financial performance as a Nasdaq-listed company. Press releases regularly highlight quarterly and annual results, revenue guidance ranges, and commentary from management on market conditions, tariffs, and geopolitical developments affecting its operating environment.
Investors following InMode news will find detailed updates on quarterly revenues, gross margins, operating income, and cash position, often presented alongside non-GAAP metrics that exclude share-based compensation and related tax adjustments. The company also issues announcements when it provides or revises full-year revenue guidance, giving insight into management’s expectations for its RF-based aesthetic and medical device business.
Another key news theme is capital markets and investor relations activity. InMode frequently announces participation in major healthcare and medical technology investor conferences hosted by firms such as UBS, Jefferies, Canaccord Genuity, Baird, and Needham. These items describe fireside chats, formal presentations, and one-on-one investor meetings featuring senior executives, as well as links to live webcasts and replays.
Corporate governance and shareholder matters also appear in the news flow. For example, an external stockholder, DOMA Perpetual Capital Management LLC, publicly released a letter urging InMode’s board to expand capital returns to shareholders, focusing on share repurchases and discussing the company’s cash position and valuation. In addition, InMode has announced leadership changes, such as the appointment of a President of North America, reflecting developments in its organizational structure and regional strategy.
By tracking INMD news, readers can monitor earnings releases, guidance updates, conference participation, shareholder communications, and leadership announcements that together provide a current picture of how InMode presents its business and responds to financial and market dynamics.
InMode Ltd. (NASDAQ: INMD) announced on March 13, 2023, that it does not hold cash or securities at Silicon Valley Bank. The company keeps its cash and non-insured deposits in U.S. money center banks and major Israeli financial institutions. Consequently, InMode does not anticipate any operational impact from the bank's closure. The company will continue to monitor potential effects on its suppliers, vendors, and other partners.
InMode is recognized for its innovative medical technologies, particularly those utilizing radiofrequency (RF) technology, serving various medical fields including plastic surgery and dermatology.
InMode Ltd. (NASDAQ: INMD), a global leader in innovative medical technologies, announced that its CFO Yair Malca and CMO Spero Theodorou will present at the Barclays Global Health Conference in Miami on March 15, 2023. The presentation is set for 9:30 am ET and will be moderated by equity research analyst Matt Miksic. Interested parties can access the webcast via InMode's Investor Relations website. InMode will also hold one-on-one investor meetings that day. For further details, visit the investor relations site.
InMode Ltd. (Nasdaq: INMD) reported record financial results for Q4 and FY 2022. Q4 revenue reached $133.6 million, a 21% increase from Q4 2021, with 83% from surgical technology platforms. GAAP net income for Q4 was $37.7 million, while non-GAAP net income hit $66.4 million. For the full year, revenues reached $454.3 million, a 27% increase, with GAAP net income of $161.5 million. Looking ahead, InMode forecasts revenue between $525 million and $530 million for 2023. Investors can expect a non-GAAP EPS of $2.58 to $2.60.
InMode Ltd. (Nasdaq: INMD) is set to announce its financial results for Q4 and the full year 2022 on February 14, 2023. Preliminary estimates indicate record revenues between $133.2 million and $133.4 million for Q4 2022, and $453.9 million to $454.1 million for the full year. Non-GAAP earnings per diluted share are expected to be $0.73 to $0.74 for Q4 and $2.38 to $2.39 for 2022. Additionally, the company projects 2023 revenues between $525 million and $530 million. InMode will hold a conference call on February 14 at 8:30 a.m. ET to discuss the results.
InMode Ltd. (Nasdaq: INMD) announced that its leadership team, including Moshe Mizrahy (CEO), Yair Malca (CFO), and Spero Theodorou (CMO), will present at the 25th Annual Needham Growth Conference on Jan. 12, 2023. The event, moderated by Mike Matson, starts at 10:15 am Eastern Time and will be accessible via webcast on InMode's Investor Relations website. Additionally, InMode will conduct in-person meetings on Jan. 11 and virtual meetings on Jan. 12.
InMode Ltd. (Nasdaq: INMD), a global leader in medical technologies, announced participation in three major investor conferences in November and December 2022. The events include:
- Jefferies London Healthcare Conference: Presentation on November 15 at 10:20 a.m. GMT
- Canaccord Genuity MTDF Conference: Presentation on November 17 at 1:00 p.m. ET
- Cantor Medical & Aesthetic Dermatology Conference: Panel on December 8 at 1:45 p.m. ET
Live webcasts will be available for each presentation. For more details, visit InMode's website.
InMode Ltd. (Nasdaq: INMD) reported a record-breaking revenue of $121.2 million for Q3 2022, marking a 29% increase compared to Q3 2021. The company achieved a GAAP net income of $48.8 million or $0.58 per diluted share, up from $44.7 million or $0.52 in the previous year. Non-GAAP net income reached $56.6 million with a non-GAAP EPS of $0.66. Significant growth was seen in consumables and services, increasing 53% year-over-year to $13.9 million. Management also increased revenue targets for the EmpowerRF platform and plans global expansion.
InMode Ltd. (Nasdaq: INMD) anticipates record third-quarter revenue between $120.5 million and $120.9 million, alongside a projected non-GAAP gross margin of 84% to 85% and earnings per diluted share ranging from $0.64 to $0.65. The company has also raised its full-year 2022 revenue guidance to between $445 million and $450 million. A conference call to discuss these results is scheduled for October 27, 2022, at 8:30 a.m. ET.
On September 29, 2022, InMode Ltd. (Nasdaq: INMD) announced actress Eva Longoria as its Global Brand Ambassador. Longoria, known for her work on Desperate Housewives and her philanthropic efforts, will promote InMode's innovative medical technologies. She has personally utilized InMode’s EvolveX Transform and Morpheus8 Body treatments to address post-pregnancy body changes, emphasizing their effectiveness. InMode develops and markets cutting-edge devices leveraging radiofrequency technology across multiple medical fields, striving to enhance surgical procedures and existing treatments.
InMode Ltd. (Nasdaq: INMD) announced that CFO Yair Malca will present at the Baird 2022 Global Healthcare Conference on Sept. 13, 2022, at 1:25 pm Eastern Time at the InterContinental New York Barclay hotel. The presentation will be webcast on InMode's Investor Relations website. Malca will also hold one-on-one investor meetings on Sept. 13 and Sept. 14. InMode specializes in innovative medical technologies, focusing on minimally invasive RF technologies applicable in various medical fields.
FAQ
What is the current stock price of Inmode Ltd. (INMD)?
What is the market cap of Inmode Ltd. (INMD)?
